TIPSS术使用组合支架与Viatorr支架治疗肝硬化并发门静脉高压症患者长期疗效比较*

doi:10.3969/j.issn.1672-5069.2024.04.023

实用肝脏病杂志 ›› 2024, Vol. 27 ›› Issue (4): 583-586.doi: 10.3969/j.issn.1672-5069.2024.04.023

TIPSS术使用组合支架与Viatorr支架治疗肝硬化并发门静脉高压症患者长期疗效比较^*

鲍应军, 张媛, 顾俊鹏, 朱帝文, 张海潇, 曹耿飞, 阿斯哈尔·哈斯木, 任伟新

830054 乌鲁木齐市新疆医科大学第一附属医院介入放射科(鲍应军,顾俊鹏,朱帝文,张海潇,曹耿飞,阿斯哈尔·哈斯木,任伟新) ;附属肿瘤医院超声诊断科(张媛)

收稿日期:2023-12-08 出版日期:2024-07-10 发布日期:2024-07-10
通讯作者: 任伟新,E-mail:rwx1031@163.com
作者简介:鲍应军,男,36岁,博士研究生,主治医师。主要从事肝硬化门静脉高压症介入诊断与治疗研究。E-mail:baodazi@126.com
基金资助:
^*新疆维吾尔自治区“天池英才”青年博士资助项目(编号:2020001)

Combined stents versus Viatorr stents in transjugular intrahepatic portosystemic stent shunt for treatment of patients with liver cirrhosis and complicated portal hypertension

Bao Yingjun, Zhang Yuan, Gu Junpeng, et al

Department of Interventional Radiology, First Affiliated Hospital,Xinjiang Medical University, Urumqi 830054, Xinjiang Uygur Autonomous Region, China

Received:2023-12-08 Online:2024-07-10 Published:2024-07-10

摘要/Abstract

摘要： 目的探讨经颈静脉肝内门体静脉分流术(TIPSS)中使用组合支架与Viatorr支架的长期疗效。方法 2013年7月～2022年8月新疆医科大学第一附属医院介入治疗中心诊治的肝硬化并发门静脉高压症患者51例,均接受TIPSS术治疗,其中使用组合支架29例,使用Viatorr支架22例。术后随访5年。使用影像学检查肝内分流道通畅情况,应用Kaplan-Meler法分析比较两组分流道累积通畅率和生存率。结果使用Viatorr支架手术花费为73282.9(68190.6,81242.2)元,显著高于使用组合支架【61912.7(53713.6,67530.3)元,P<0.05】;第一年、二年、三年、四年和五年,Viatorr支架组肝内分流道累积通畅率分别为90.9%、77.3%、72.7%、71.4%和68.4%,组合支架组分别为86.7%、80.0%、76.7%、73.3%和70.0%,两组无统计学差异(P＞0.05);Viatorr支架组累计生存率分别为95.5%、77.3%、72.7%、68.2%和59.1%,组合支架组分别为93.3%、86.7%、83.3%、83.3%和79.9%,两组无统计学差异(P＞0.05)。结论本组资料显示,在行TIPSS手术时使用组合支架或Viatorr支架均可获得较好的临床效果,可根据供给情况选择使用。

关键词: 肝硬化, 门脉高压症, 经颈静脉肝内门体静脉分流术, 组合支架, Viatorr支架, 治疗

Abstract: Objective This study was conducted to investigate the long-term efficacy of combined stents and Viatorr stents in transjugular intrahepatic portosystemic stent shunt (TIPSS) for treatment of patients with liver cirrhosis (LC) and complicated portal hypertension (PH). Methods All patients in our series underwent TIPSS, 29 patients were assigned to combined stents and 22 to Viatorr stents and all were followed-up for five years. The patency of the intrahepatic shunts were check-up by ultrasonography or/and CT scan. The survival was compared by Kaplan-Meier method. Results The operational costs in patients in Viatorr group was 73282.9(68190.6, 81242.2)yuan, much greater than [61912.7(53713.6,67530.3)yuan, P<0.05] in patients in combined stents; at the end of one, two, three, four and five years after TIPSS, the cumulative patency of intrahepatic stents in patients with Viatorr were 90.9%, 77.3%, 72.7%, 71.4% and 68.4%, and they were 86.7%, 80.0%, 76.7%, 73.3% and 70.0% in patients with combined stents, not significantly different between the two groups (P＞0.05); the cumulative survival rates in patients with Viatorr stent were 95.5%, 77.3%, 72.7%, 68.2% and 59.1%, also not significantly different as compared to 93.3%, 86.7%, 83.3%, 83.3% and 79.9% in patients with combined stents (P＞0.05). Conclusion We recommend the choice of combined stents or Viatorr stents for TIPSS surgery as the supply available, as the two have a relatively similar promising efficacy in dealing with cirrhotics with PH.

Key words: Liver cirrhosis, Portal hypertension, Transjugular intrahepatic portosystemic stent shunt, Combined stents, Viatorr stents, Therapy

鲍应军, 张媛, 顾俊鹏, 朱帝文, 张海潇, 曹耿飞, 阿斯哈尔·哈斯木, 任伟新. TIPSS术使用组合支架与Viatorr支架治疗肝硬化并发门静脉高压症患者长期疗效比较^*[J]. 实用肝脏病杂志, 2024, 27(4): 583-586.

Bao Yingjun, Zhang Yuan, Gu Junpeng, et al. Combined stents versus Viatorr stents in transjugular intrahepatic portosystemic stent shunt for treatment of patients with liver cirrhosis and complicated portal hypertension[J]. Journal of Practical Hepatology, 2024, 27(4): 583-586.

参考文献

[1] Allaire M, Walter A, Sutter O, et al. TIPS for management of portal-hypertension-related complications in patients with cirrhosis. Clin Res Hepatol Gastroenterol, 2020,44(3):249-263.
[2] Gines P,Krag A,Abraldes JG,et al. Liver cirrhosis.Lancet,2021,398( 10308) : 1359-1376.
[3] Zanetto A, Barbiero G, Battistel M, et al. Management of portal hypertension severe complications. Minerva Gastroenterol (Torino), 2021,67(1):26-37.
[4] Engelmann C, Clària J, Szabo G, et al. Pathophysiology of decompensated cirrhosis: Portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction. J Hepatol,2021,75 (1):S49-S66.
[5] Abraldes JG, Caraceni P, Ghabril M, et al. Update in the treatment of the complications of cirrhosis. Clin Gastroenterol Hepatol,2023,21(8):2100-2109.
[6] 胡锦华,李涛,崔屹,等.影像融合技术在经颈静脉肝内门体分流术门静脉穿刺引导中的应用进展.中华消化病与影像杂志,2022,12(5):302-305.
[7] Boike JR, Thornburg BG, Asrani SK,et al. North American Practice-Based Recommendations for transjugular intrahepatic portosystemic shunts in portal hypertension. Clin Gastroenterol Hepatol, 2022,20(8):1636-1662.
[8] 周艳峰,方主亭,唐仪,等.Viatorr 支架在门静脉高压合并上消化道出血的临床应用.中华介入放射学电子杂志,2018,6(3):237-242.
[9] 亓皓亮,王广川,张明艳,等.Viatorr覆膜支架在经颈静脉肝内门体静脉分流术中的临床应用.中华消化病与影像杂志,2017,7(5):200-204.
[10] Lau LHS, Sung JJY. Treatment of upper gastrointestinal bleeding in 2020: New techniques and outcomes. Dig Endosc, 2021,33(1):83-94.
[11] Dunne PDJ, Sinha R, Stanley AJ, et al. Randomised clinical trial: standard of care versus early-transjugular intrahepatic porto-systemic shunt (TIPSS) in patients with cirrhosis and oesophageal variceal bleeding. Aliment Pharmacol Ther,2020,52(1):98-106.
[12] Busk TM, Bendtsen F, Poulsen JH, et al. Transjugular intrahepatic portosystemic shunt: impact on systemic hemodynamics and renal and cardiac function in patients with cirrhosis. Am J Physiol Gastrointest Liver Physiol, 2018,314(2):G275-G286.
[13] Ma L, Ma J, Zhang W, et al. Acute hepatic ischemia after transjugular intrahepatic portosystemic shunt creation despite preserved arterial perfusion. J Vasc Interv Radiol, 2021,32(10):1510-1512.
[14] Schultheiss M, Bettinger D, Sturm L, et al. Comparison of the covered self-expandable Viatorr CX stent with the covered balloon-expandable be graft peripheral stent for transjugular intrahepatic portosystemic shunt (TIPS) creation: a single-centre retrospective study in patients with variceal bleeding. Cardiovasc Intervent Radiol, 2022,45(5):542-549.
[15] Li YH, Wan YM, Wu HM, et al. Elective transjugular intrahepatic portosystemic shunt using Viatorr stent-frafts: A single-center experience from China. J Belg Soc Radiol,2022,106(1):62.
[16] 赵凯,薛晋峰,薛鹏飞,等. Viatorr覆膜支架用于TIPS术治疗肝硬化门静脉高压症患者预后研究.实用肝脏病杂志,2021,24(3):419-422.
[17] Wu HM, Huang SQ, Wan YM, et al. Clinical outcomes of transjugular intrahepatic portosystemic shunt (Tips) creation using fluency versus Viatorr stent-grafts: A single-centre retrospective study. Cardiovasc Intervent Radiol, 2022,45(5):552-562.
[18] Loomba R, Abdelmalek MF, Armstrong MJ, et al. Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol Hepatol, 2023,8(6):511-522.
[19] Miraglia R, Maruzzelli L, Di Piazza A, et al. Transjugular intrahepatic portosystemic shunt using the new core Viatorr controlled expansion endoprosthesis: Prospective, single-center, preliminary experience. Cardiovasc Intervent Radiol, 2019,42(1):78-86.
[20] Dell T, Menne M, Wagenpfeil J, et al. How controlled is the expansion of VIATORR CX? Cardiovasc Intervent Radiol,2023,46(5):658-663.

TIPSS术使用组合支架与Viatorr支架治疗肝硬化并发门静脉高压症患者长期疗效比较^*

Combined stents versus Viatorr stents in transjugular intrahepatic portosystemic stent shunt for treatment of patients with liver cirrhosis and complicated portal hypertension

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	陈思彤, 卫小蝶, 韦新焕, 郭海清, 张晶. 代谢功能障碍相关脂肪性肝病诊疗进展^*[J]. 实用肝脏病杂志, 2024, 27(4): 481-483.
[2]	柳雅立, 张晶. 儿童和青少年代谢相关脂肪性肝病研究进展^*[J]. 实用肝脏病杂志, 2024, 27(4): 488-491.
[3]	中华医学会肝病学分会. 代谢相关(非酒精性)脂肪性肝病防治指南(2024年版)[J]. 实用肝脏病杂志, 2024, 27(4): 494-510.
[4]	张全乐, 赵丹, 李杰, 刘三香, 刘刚, 李亚. 富马酸替诺福韦与恩替卡韦挽救治疗拉米夫定耐药的HBeAg阴性慢性乙型肝炎患者疗效分析^*[J]. 实用肝脏病杂志, 2024, 27(4): 515-518.
[5]	薛李娜, 诸国兵, 吴琳霖, 杨小星. TAF治疗ETV经治的低病毒血症慢性乙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(4): 519-522.
[6]	张丽, 陈雅雯, 盖琳, 邱红, 甄鑫, 常静霞. 乙型肝炎病毒/丙型肝炎病毒共同感染患者临床特征及其对抗病毒治疗应答反应研究^*[J]. 实用肝脏病杂志, 2024, 27(4): 523-526.
[7]	任浩, 熊清芳. 多种无创检测指标预测自身免疫性肝病患者肝硬化效能比较^*[J]. 实用肝脏病杂志, 2024, 27(4): 535-538.
[8]	蒋瑶, 仲伟明, 周俏怡, 邵宁, 吕冰, 孙舒. 吗替麦考酚酯治疗难治性自身免疫性肝炎患者疗效初步研究^*[J]. 实用肝脏病杂志, 2024, 27(4): 539-542.
[9]	赵维波, 王源, 孔令甲, 朱玉森, 岳宗柱, 商西单. 球囊压迫辅助下内镜硬化剂注射治疗乙型肝炎肝硬化并发食管静脉曲张患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(4): 559-562.
[10]	邢世磊, 李之慧, 宁秀景. 乙型肝炎肝硬化并发自发性细菌性腹膜炎患者血清MCP-1、TNF-α和IL-10水平变化及其与病情复发的关系研究^*[J]. 实用肝脏病杂志, 2024, 27(4): 563-566.
[11]	艾孜江·艾买提, 阿布都西库尔·阿布都米吉提, 迪丽努尔·阿卜杜热合曼, 吴源泉. 骨髓间充质干细胞移植联合自拟中药治疗失代偿期肝硬化患者效果研究^*[J]. 实用肝脏病杂志, 2024, 27(4): 567-570.
[12]	樊亚楠, 纪童童, 李鑫飞, 于岩岩, 彭虹, 徐小元, 徐京杭. 两中心肝硬化住院患者病因构成和并发症分布研究[J]. 实用肝脏病杂志, 2024, 27(4): 571-574.
[13]	李维新, 索爱军, 王秀峰. 地佐辛联合丙泊酚靶控输注处理接受内镜下注射硬化剂治疗的乙型肝炎肝硬化并发食管静脉曲张破裂出血患者麻醉苏醒和镇痛效果研究^*[J]. 实用肝脏病杂志, 2024, 27(4): 575-578.
[14]	汤泽宇, 顾菲, 周健文, 姜小兰, 毛雨婧, 樊琦. CT参数联合FIB-4和血清VEGF水平预测乙型肝炎肝硬化患者并发食管静脉曲张效能分析^*[J]. 实用肝脏病杂志, 2024, 27(4): 579-582.
[15]	王秀芝, 常金, 宋丹, 谭亭昭. 卡瑞利珠单抗联合阿帕替尼治疗晚期原发性肝癌患者效果研究^*[J]. 实用肝脏病杂志, 2024, 27(4): 591-594.